Can our national health system sustain these prices?

Can our national health system sustain these prices?

Today in the UKinfo-icon, doctors have to tell patients that they could cure them using a specific medicine, but cannot prescribe it because it’s too expensive. To avoid the collapse of our health service, the British Government has established selection strategies to decide which patients can benefit from treatment. Therefore, today out of the 215,000 people suffering from chronic Hepatitis C, only those patients at advanced stage disease are entitled to treatment and care, that’s just 3,500 patients means only 1.5% of patients.

What does the government do?

Patents protecting therapeutic innovations have a shelf life of 20 years, during which a cheaper generic version cannot be launched. However, the government does not use available tools to oppose this, such as compulsory licenses. This provision means that a patent can be temporarily suspended and the market opened up to competition in order to produce or import generics and reduce prices. The UKinfo-icon Patents Act 1977, provides for the grant of compulsory licences under patents in circumstances where it can be established that there has been an abuse of the monopoly rights in relation to such patents. In practice though, compulsory licences are rarely applied for in the UKinfo-icon.


What does the government say?

“The government intends to reform the way in which drugs purchased by the NHS are priced. It aims to ensure that drug costs more fully reflect clinical benefit and to improve patient access to new treatments”


In a bid to provide access to innovative and quality treatment at the best price for patients and the National Health Service, the National Institute for Health and Care Excellence (NICE) has approved the use of expensive drugs such as Sofosbuvir (Sovaldi) to allow the British public access to new medicines. However, the NHS is forced to delay its introduction due to its highly expensive price. Sofosbuvir (Sovaldi) can save the lives of people infected with the hepatitis C virus and is currently recognised by NICE as “cost-effective”, because it is a cure for people who would otherwise run up huge NHS bills.

NICE judge’s medicines and their suitability for the NHS using a Quality-adjusted life year score (QALYS). QALYs are calculated by estimating the years of life remaining for a patient following a particular treatment or intervention and weighting each year with a quality-of-life score (on a 0 to 1 scale). It is often measured in terms of the person’s ability to carry out the activities of daily life, and freedom from pain and mental disturbance.

One in three people infected with hepatitis C will develop liver cirrhosis and some will get cancer. At this stage of the disease, a liver transplant is the only option. Currently, this operation costs more than £50,000 on the NHS and poses complex donor and recipient concerns. Sofosbuvir (Sovaldi) can be used to prevent this and when combined with Ribavirin it cures 95% of patients. As the Government pushes for innovative treatments that provide clinical benefit, Sofosbuvir (Sovaldi) is a prime example of the medicines we should be able to access. Due to Sofosbuvir and Ribavirin’s combinational costs, a cost of £1bn for every 20,000 people treated on the NHS, leaves the Government and NHS caught at a cross-road between prices or patients.



Your support

I make a donation.

Join us

I apply online.


I subscribe to the newsletter.